English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 46833/50693 (92%)
造訪人次 : 11845085      線上人數 : 388
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於CCUR管理 到手機版


    請使用永久網址來引用或連結此文件: https://irlib.pccu.edu.tw/handle/987654321/20951


    題名: CONCURRENT CHEMORADIOTHERAPY WITH HELICAL TOMOTHERAPY FOR OROPHARYNGEAL CANCER: A PRELIMINARY RESULT
    作者: Shueng, PW (Shueng, Pei-Wei)
    Wu, LJ (Wu, Le-Jung)
    Chen, SY (Chen, Shiou-Yi)
    Hsiao, CH (Hsiao, Chi-Huang)
    Tien, HJ (Tien, Hui-Ju)
    Cheng, PW (Cheng, Po-Wen)
    Kuo, YS (Kuo, Ying-Shiung)
    Chen, YJ (Chen, Yu-Jen)
    Chen, CA (Chen, Chien-An)
    Hsieh, PY (Hsieh, Pei-Ying)
    Hsieh, CH (Hsieh, Chen-Hsi)
    貢獻者: 運教所
    關鍵詞: Concurrent chemoradiation
    Helical tomotherapy
    Intensity-modulated radiotherapy
    Oropharyngeal cancer
    日期: 2010-07
    上傳時間: 2011-12-09 14:57:48 (UTC+8)
    摘要: Purpose: To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer.

    Methods and Materials: Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70Gy, 63Gy, and 56Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30mg/m(2), plus 5-fluorouracil (425mg/m(2))/leucovorin (30mg/m(2)) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose volume histograms.

    Results: The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9Gy, respectively. No Grade 3 toxicity for dermatitis and body weight loss and only one instance of Grade 3 mucositis were noted.

    Conclusion: Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings. (C) 2010 Elsevier Inc.
    顯示於類別:[運動教練研究所] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML700檢視/開啟


    在CCUR中所有的資料項目都受到原著作權保護.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋